Component
Human complement fragment C3b
Human complement fragment C3b
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
RA inhibited covalent C3b attachment to surfaces with an IC50 of 34 micromolar.
Experimental context and source evidence
- evidence_access
- Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
- experimental_contrast
- {"intervention": "RA during nascent C3b attachment", "comparator": "No RA", "endpoint": "RA inhibited covalent C3b attachment to surfaces with an IC50 of 34 micromolar.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; recorded from source.
- experimental_model
- Purified human complement proteins and cells.
- interpretation_status
- Recorded from source with stated access limits; ungraded, not independent replication.
- limitations
- Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
- nutrient_topic
- Rosmarinic acid collection; exact intervention and molecular form govern interpretation. · Rosmarinic acid
- plain_language
- RA inhibited covalent C3b attachment to surfaces with an IC50 of 34 micromolar.
- primary_references
- Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b. | https://pubmed.ncbi.nlm.nih.gov/10353266/ | https://doi.org/10.1016/s0006-2952(99)00044-1
- source_locator
- Reviewed reference ra-c3b-attachment; Radiolabel entered the activated thioester-containing C3b chain, supporting direct interception.
Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026) · lines 213–219
AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · Purified human complement proteins and cells. · Recorded from source · Recorded from source
### ra-c3b-attachment RA inhibited covalent C3b attachment to surfaces with an IC50 of 34 micromolar. Radiolabel entered the activated thioester-containing C3b chain, supporting direct interception. Model and exposure: Purified human complement proteins and cells. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b. | 1999 | https://pubmed.ncbi.nlm.nih.gov/10353266/ | https://doi.org/10.1016/s0006-2952(99)00044-1 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
Complete structured claim and evidence
Where it participates (unsigned role)
RA inhibited classical- and alternative-pathway hemolysis at IC50 values of 180 and 160 micromolar.
Experimental context and source evidence
- evidence_access
- Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
- experimental_contrast
- {"intervention": "RA", "comparator": "No RA", "endpoint": "RA inhibited classical- and alternative-pathway hemolysis at IC50 values of 180 and 160 micromolar.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; recorded from source.
- experimental_model
- Human serum hemolytic assays.
- interpretation_status
- Recorded from source with stated access limits; ungraded, not independent replication.
- limitations
- Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
- nutrient_topic
- Rosmarinic acid collection; exact intervention and molecular form govern interpretation. · Rosmarinic acid
- plain_language
- RA inhibited classical- and alternative-pathway hemolysis at IC50 values of 180 and 160 micromolar.
- primary_references
- Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b. | https://pubmed.ncbi.nlm.nih.gov/10353266/ | https://doi.org/10.1016/s0006-2952(99)00044-1
- source_locator
- Reviewed reference ra-complement-lysis;
Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026) · lines 237–243
AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · Human serum hemolytic assays. · Recorded from source · Recorded from source
### ra-complement-lysis RA inhibited classical- and alternative-pathway hemolysis at IC50 values of 180 and 160 micromolar. Model and exposure: Human serum hemolytic assays. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b. | 1999 | https://pubmed.ncbi.nlm.nih.gov/10353266/ | https://doi.org/10.1016/s0006-2952(99)00044-1 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.